Abstract
Two phaseⅢclinical trials of gefitinib in combination with chemotherapy(INTACT-1 andINTACT-2)showed that gefitinib in combination with gemcitabine and cisplatin or paclitaxel and carboplatin in Datients with advanced non-small cell lung cancer did not improve efficacy over chemotherapy alone.This negative resuIt may due to the lack of careful selection of sensitive populations and the antagonism between the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)and chemotherapeutic agents.The potential combination using sequential EGFR-TKI after chemotherapy or intermittent high-dose EGFR-TKI during chemotherapy might have decent clinical prospect,show promise in some preclinical and clinical trials. Key words: Epidermal growth factor receptor tyrosine kinase inhibitors; Chemotherapy; Non-small cell lung cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
